Observatoire des droits humains (anglais seulement)

The weight-loss drug divide: private prescribing is lowest where need is greatest

(Version anglaise seulement)

par Rachel Woods, Associate Professor of Medical Education, University of Nottingham; University of Lincoln

For many people living with obesity, Wegovy and Mounjaro offer the possibility of substantial weight loss without surgery. Yet data from one private provider points to a troubling divide: prescription rates of these drugs in England are lowest in communities where obesity is most common.

Wegovy contains semaglutide, which acts on the GLP-1 hormone pathway involved in appetite. Mounjaro contains tirzepatide, which targets both GLP-1 and another hormone pathway called…

Lire l'article complet